

# The N Domain of Human Angiotensin-I-converting Enz

Journal of Biological Chemistry

285, 35685-35693

DOI: [10.1074/jbc.m110.167866](https://doi.org/10.1074/jbc.m110.167866)

Citation Report

#	ARTICLE	IF	CITATIONS
1	An Angiotensin I-Converting Enzyme Mutation (Y465D) Causes a Dramatic Increase in Blood ACE via Accelerated ACE Shedding. PLoS ONE, 2011, 6, e25952.	1.1	37
2	Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide. Biochemical Journal, 2011, 436, 53-59.	1.7	36
3	Remarkable Potential of the Î±-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry. Journal of Medicinal Chemistry, 2011, 54, 5955-5980.	2.9	529
4	Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis and Tissue Repair, 2011, 4, 25.	3.4	23
5	Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors. Current Medicinal Chemistry, 2012, 19, 845-855.	1.2	47
6	Characterization of angiotensin I-converting enzyme N-domain selectivity using positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides. Biological Chemistry, 2012, 393, 1547-1554.	1.2	3
7	Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Scientific Reports, 2012, 2, 717.	1.6	127
8	Molecular mechanism of the interactions between inhibitory tripeptides and angiotensin-converting enzyme. Biophysical Chemistry, 2012, 168-169, 60-66.	1.5	21
9	Inhibition of Angiotensin-Converting Enzyme Activity by Flavonoids: Structure-Activity Relationship Studies. PLoS ONE, 2012, 7, e49493.	1.1	257
10	Predictive modelling of angiotensin converting enzyme inhibitory dipeptides. Food Chemistry, 2012, 133, 1349-1354.	4.2	73
11	Peptidyl-Dipeptidase A/Angiotensin I-Converting Enzyme. , 2013, , 480-494.		13
12	A Modern Understanding of the Traditional and Nontraditional Biological Functions of Angiotensin-Converting Enzyme. Pharmacological Reviews, 2013, 65, 1-46.	7.1	240
13	The structure of human Î±-2,6-sialyltransferase reveals the binding mode of complex glycans. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 1826-1838.	2.5	71
14	Peptide Degradation (Nepriylsin and Other Regulatory Peptidases). , 2013, , 1757-1764.		4
15	A Novel Angiotensin I-Converting Enzyme Mutation (S333W) Impairs N-Domain Enzymatic Cleavage of the Anti-Fibrotic Peptide, AcSDKP. PLoS ONE, 2014, 9, e88001.	1.1	19
16	N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes. Frontiers in Pharmacology, 2014, 5, 70.	1.6	26
17	Fragment-based design for the development of N-domain-selective angiotensin-I-converting enzyme inhibitors. Clinical Science, 2014, 126, 305-313.	1.8	36
18	N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition. BioMed Research International, 2014, 2014, 1-12.	0.9	73

#	ARTICLE	IF	CITATIONS
19	Phosphinic Peptides as Potent Inhibitors of Zinc-Metalloproteases. Topics in Current Chemistry, 2014, 360, 1-38.	4.0	32
20	ACE for all â€“ a molecular perspective. Journal of Cell Communication and Signaling, 2014, 8, 195-210.	1.8	30
21	Seafood Processing By-products: Collagen and Gelatin. , 2014, , 207-242.		10
22	Absence of cell surface expression of human ACE leads to perinatal death. Human Molecular Genetics, 2014, 23, 1479-1491.	1.4	14
23	Angiotensin-I converting enzyme (ACE): structure, biological roles, and molecular basis for chloride ion dependence. Biological Chemistry, 2014, 395, 1135-1149.	1.2	43
24	How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor. Drug Discovery Today, 2014, 19, 1731-1743.	3.2	23
25	Molecular and Thermodynamic Mechanisms of the Chloride-dependent Human Angiotensin-I-converting Enzyme (ACE). Journal of Biological Chemistry, 2014, 289, 1798-1814.	1.6	29
26	Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensinâ€‹<sc>I</sc> converting enzyme. FEBS Journal, 2014, 281, 943-956.	2.2	27
27	QM/MM Study and MD Simulations on the Hypertension Regulator Angiotensin-Converting Enzyme. ACS Catalysis, 2014, 4, 2587-2597.	5.5	23
28	Interkingdom Pharmacology of Angiotensin-I Converting Enzyme Inhibitor Phosphonates Produced by Actinomycetes. ACS Medicinal Chemistry Letters, 2014, 5, 346-351.	1.3	26
30	Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme. Scientific Reports, 2015, 5, 13742.	1.6	18
31	Using Crystallographic Data To Facilitate Studentsâ€™™ Discovery of How Protein Models Are Producedâ€“An Activity Illustrating the Effect of Resolution on Model Quality. Journal of Chemical Education, 2015, 92, 2117-2119.	1.1	2
32	Analysis of carbohydrates and glycoconjugates by matrixâ€‹<sc>I</sc>-assisted laser desorption/ionization mass spectrometry: An update for 2009â€“2010. Mass Spectrometry Reviews, 2015, 34, 268-422.	2.8	63
33	Crystal structure of a peptidylâ€‹<sc>I</sc>-dipeptidase Kâ€‹<sc>26â€‹<sc>DCP from <i>Actinomycete</i> in complex with its natural inhibitor. FEBS Journal, 2016, 283, 4357-4369.	2.2	6
34	Kinetic and structural characterization of amyloidâ€‹<sc>2</sc> peptide hydrolysis by human angiotensinâ€‹<sc>I</sc>-converting enzyme. FEBS Journal, 2016, 283, 1060-1076.	2.2	19
35	The effect of structural motifs on the ectodomain shedding of human angiotensin-converting enzyme. Biochemical and Biophysical Research Communications, 2016, 481, 111-116.	1.0	6
36	The toxicity of angiotensin converting enzyme inhibitors to larvae of the disease vectors Aedes aegypti and Anopheles gambiae. Scientific Reports, 2017, 7, 45409.	1.6	7
37	Predictions for Î±-Helical Glycopeptide Design from Structural Bioinformatics Analysis. Journal of Chemical Information and Modeling, 2017, 57, 2598-2611.	2.5	2

#	ARTICLE	IF	CITATIONS
38	Crystal structures of sampatrilat and sampatrilatâ€Asp in complex with human ACE â€“ a molecular basis for domain selectivity. <i>FEBS Journal</i> , 2018, 285, 1477-1490.	2.2	23
39	The Design and Development of a Potent and Selective Novel Diprolyl Derivative That Binds to the N-Domain of Angiotensin-I Converting Enzyme. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 344-359.	2.9	20
40	The Coming of Age of the Angiotensin Hypothesis in Alzheimerâ€™s Disease: Progress Toward Disease Prevention and Treatment?. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1443-1466.	1.2	105
41	Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain: Implications for Drug Design. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10141-10154.	2.9	22
42	Interacting cogs in the machinery of the renin angiotensin system. <i>Biophysical Reviews</i> , 2019, 11, 583-589.	1.5	3
43	Structural basis for the C-domain-selective angiotensin-converting enzyme inhibition by bradykinin-potentiating peptide b (BPPb). <i>Biochemical Journal</i> , 2019, 476, 1553-1570.	1.7	16
44	In silico identification of angiotensin-1 converting enzyme inhibitors using text mining and virtual screening. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, , 1-11.	2.0	1
45	Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. <i>Infection, Genetics and Evolution</i> , 2020, 85, 104510.	1.0	9
46	Synopsis of recent synthetic methods and biological applications of phosphinic acid derivatives. <i>Tetrahedron</i> , 2020, 76, 131251.	1.0	19
47	Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors. <i>Molecules</i> , 2020, 25, 295.	1.7	35
48	Novel ACE mutations mimicking sarcoidosis by increasing blood ACE levels. <i>Translational Research</i> , 2021, 230, 5-20.	2.2	12
49	Angiotensinâ€converting enzyme open for business: structural insights into the subdomain dynamics. <i>FEBS Journal</i> , 2021, 288, 2238-2256.	2.2	21
50	Molecular dynamics investigation on the interaction of human angiotensin-converting enzyme with tetrapeptide inhibitors. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 6685-6694.	1.3	6
51	Human angiotensin Iâ€converting enzyme study by surfaceâ€enhanced Raman spectroscopy. <i>Journal of Raman Spectroscopy</i> , 2021, 52, 1529-1539.	1.2	8
52	Structure-Based Design of Domain-Selective Angiotensin-Converting Enzyme Inhibitors. , 2012, , 355-377.		2
53	Crystal structures of angiotensin-converting enzyme from <i>Anopheles gambiae</i> in its native form and with a bound inhibitor. <i>Biochemical Journal</i> , 2019, 476, 3505-3520.	1.7	6
54	ACE-domain selectivity extends beyond direct interacting residues at the active site. <i>Biochemical Journal</i> , 2020, 477, 1241-1259.	1.7	10
55	ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV. <i>Clinical Science</i> , 2020, 134, 2851-2871.	1.8	47

#	ARTICLE	IF	CITATIONS
56	Transforming Non-Selective Angiotensin-Converting Enzyme Inhibitors in C- and N-domain Selective Inhibitors by Using Computational Tools. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020, 20, 1436-1446.	1.1	3
57	The Synthesis and In Silico Antihypertensive Activity Prognosis of New Mannich Bases Containing the 1,2,4-Triazole Moiety. <i>Chemistry and Chemical Technology</i> , 2020, 14, 214-220.	0.2	6
58	Comparative N-Glycoproteomic Analysis Provides Novel Insights into the Deterioration Mechanisms in Chicken Egg Vitelline Membrane during High-Temperature Storage. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 2354-2363.	2.4	4
59	Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors. <i>Medicinal Chemistry</i> , 2019, 15, 574-587.	0.7	6
60	Probing the Requirements for Dual Angiotensin-Converting Enzyme C-Domain Selective/Nepilysin Inhibition. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3371-3387.	2.9	3
61	Structural basis for the inhibition of human angiotensinâ€ converting enzyme by fosinoprilat. <i>FEBS Journal</i> , 2022, 289, 6659-6671.	2.2	5
62	A new approach for purification of the catalytic site of the angiotensin-conversion enzyme, N-domain, mediated by the ELP-Intein system. <i>Journal of Pharmacological and Toxicological Methods</i> , 2022, 116, 107174.	0.3	0
63	<scp>Cryoâ€EM</scp> reveals mechanisms of angiotensin lâ€ converting enzyme allostery and dimerization. <i>EMBO Journal</i> , 2022, 41, .	3.5	4
64	Diastereoselective synthesis of a novel phosphinic peptide as ACE inhibitor: Fragment-based design approach. <i>Arabian Journal of Chemistry</i> , 2023, 16, 104499.	2.3	1
65	Phosphinic Peptides as Tool Compounds for the Study of Pharmacologically Relevant Zn-Metalloproteases. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 1228-1253.	2.5	1
66	Urinary ACE Phenotyping as a Research and Diagnostic Tool: Identification of Sex-Dependent ACE Immunoreactivity. <i>Biomedicines</i> , 2023, 11, 953.	1.4	1
67	Blood ACE Phenotyping for Personalized Medicine: Revelation of Patients with Conformationally Altered ACE. <i>Biomedicines</i> , 2023, 11, 534.	1.4	1
68	Presenilin 1 deficiency impairs AÎ²42-to-AÎ²40- and angiotensin-converting activities of ACE. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	1.7	3